Shrimp Disease Prevention and Therapeutics Market Size, Share Detailed Report 2026 to 2035
Shrimp Disease Prevention and Therapeutics Market is estimated to grow at a 9.4% CAGR during the forecast period for 2026 to 2035.
Shrimp Disease Prevention & Therapeutics Market Size, Share & Trends Analysis Distribution by Product Type (Disease Prevention (Probiotics & Microbial Products , Vaccines & Immunostimulants , Functional Health Feeds & Nutraceuticals, Biosecurity, Disinfectants & Diagnostics , Disease-Resistant Broodstock & Genetics), Therapeutics (Antibiotics, Antiparasitic & Antifungal Agents, Antivirals & Supportive Therapeutics, Chemical Disease-Control Treatments) By Disease Type (Viral Diseases, Bacterial Diseases, Parasitic & Microsporidian Diseases, Fungal & Opportunistic Pathogens), By End-user (Grow-Out Farms, Hatcheries & Nurseries, Integrated Farming & Feed Companies, Diagnostic Laboratories & Research Institute), Route of Administration (Oral, Water / Immersion / Bath Application, Injectable Delivery, Topical & External Application, Others) and Segment Forecasts, 2026 to 2035
Shrimp farming or aquaculture remains an essential part of the global aqua-industry because food security, rural jobs, and international trade are directly supported by this industry. But these are highly susceptible to a large number of diseases that are caused because of viruses, bacteria, fungal infections, protozoa, or stressful environments that may abruptly trigger mass deaths in these organisms, thereby resulting in substantial losses for aquaculture farms. Some serious infectious diseases affecting these organisms include viral diseases like WSSV (White Spot Syndrome Virus), YHV (Yellow Head Virus), IHHN (Infectious Hypodermal & Hematopoietic Necrosis), while AHPND (Acute Hepatopancreatic Necrosis Disease) is a bacterial disease. Uncontrolled, these diseases may result in the reduced growth, survival rate, or farm productivity of these organisms.
Shrimp culture or aqua culture is still one of the important segments of the global aqua industry since food security, rural employment, and global trade are directly linked with the entire industry. However, these are extremely vulnerable to a huge number of diseases due to viruses, bacterial infections, fungus, protozoa, and hostile conditions that may suddenly cause a huge death toll among these organisms, which may directly lead to huge losses for the aqua culture industries. The important infectious diseases among these organisms and their classifications are given below: There are some dangerous infectious diseases among these organisms, namely viruses such as: WSSV (White Spot Syndrome Virus), YHV (Yellow Head Virus), and IHHN (Infectious Hypodermal and Hematopoietic Necrosis Virus); while AHPND (Acute Hepatopancreatic Necrosis Disease) is a bacterial one.
Competitive Landscape
Which are the Leading Players in the Shrimp Disease Prevention & Therapeutics Market?
the Shrimp Disease Prevention & Therapeutics Market Companies
- Zoetis Inc.
- Merck Animal Health (Merck & Co., Inc.)
- Elanco Animal Health Incorporated
- Phibro Animal Health Corporation
- Virbac S.A.
- Laboratorios HIPRA, S.A. (HIPRA)
- Benchmark Holdings plc (INVE Aquaculture & Benchmark Genetics)
- Skretting (Nutreco N.V.)
- Cargill Aqua Nutrition (Cargill, Incorporated)
- Grobest Group
- Avanti Feeds Limited
- Kemin Industries, Inc. (Kemin AquaScience)
- Organica Biotech Private Limited
- Sanzyme Biologics Private Limited
- ViAqua Therapeutics Ltd.
- Syndel Laboratories Ltd.
- Kyoto Biken Laboratories, Inc.
- Vaxxinova International B.V.
- Nisseiken Co., Ltd.
- Salem Microbes Private Limited
- Others
Market Dynamics
Driver
Rising Disease Outbreaks in Intensive Shrimp Farming
The major driver for the Shrimp Disease Prevention & Therapeutics market is the high frequency and severe economic impact of disease outbreaks in intensive shrimp farming. As the shrimp culture has gradually transitioned from low-density and extensive rearing systems towards high-density and intensive culture due to the ever-increasing global demands for shrimp, the threat of various viruses and bacteria infections such as WSSV and AHPND has significantly increased. Such occurrences have the tendency to lead to rapid and high mortality and economic losses within a short period, hence forcing the farmer to undertake measures for the prevention, detection, and treatment of the diseases. Thus, the need for the prevention and health management measures for the shrimp has become an integral and obligatory part of shrimp culture.
Restrain/Challenge
High Cost and Regulatory Constraints Limiting Market Adoption
The key challenge in the Shrimp Disease Prevention & Therapeutics market today is that the solutions available for disease prevention and treatment of shrimp are not so effective and easily accessible, owing to the cost factor and restrictions imposed by statutory bodies. This includes the cost of using advanced diagnostics, biosecurity solutions, and innovative treatments, most of them not economically viable for small and medium-scale shrimp farmers, who account for the major chunk of the production in most parts of the world. On the other hand, the restrictions imposed on the use of antibiotics and chemicals due to the rising development of antimicrobial resistance, food safety, and concerns for the environment, greatly pose a constraint on treatments available in the market.
Disease Prevention Segment is Expected to Drive the Shrimp Disease Prevention & Therapeutics Market
The segment of Disease Prevention is leading in the Shrimp Disease Prevention & Therapeutics market. This can be attributed to the increasing emphasis on biosecurity measures, probiotics, immunostimulants, functional feeds, and early diagnostics in prevention-based health management in shrimp aquaculture. Farmers are taking more interest in prevention rather than treatment methods to reduce mortality rates, decrease potential economic losses, and adhere to increasingly strict regulations with regard to antibiotic use. Because disease outbreaks can spread quickly in intensive farming, preventive solutions may be considered more cost-effective, sustainable, and reliable instead of therapeutics.
Viral Diseases Segment is Growing at the Highest Rate in the Shrimp Disease Prevention & Therapeutics Market
The Viral Diseases category is progressing at the fastest rate in the Shrimp Disease Prevention and Therapeutics industry. This is because viral shrimp diseases such as White Spot Syndrome Virus (WSSV), Yellow Head Virus (YHV), and IHHN have high incidence rates, easily spread from shrimp to shrimp, and also cause high shrimp fatalities. Once shrimp farming becomes economically successful and reaches an intensive scale globally, shrimp farmers feel that controlling viral shrimp diseases is their utmost priority, and therefore, this particular category of shrimp disease prevention and therapeutic products is also increasing at a fast rate.
Why Asia-Pacific Led the Shrimp Disease Prevention & Therapeutics Market?
The Asia-Pacific dominated the Shrimp Disease Prevention & Therapies market. The dominance in the region was fueled by the large-scale shrimp production base in countries such as China, India, Vietnam, Indonesia, and Thailand, where shrimp farming can be considered intensive and prone to disease. Outbreaks in the region due to diseases, driven by increasing adoption for export and bio-security and health care solutions for prevention, contributed largely to the growth in the regional market.
Shrimp Disease Prevention & Therapeutics Market Report Scope:
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 9.4% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2021 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product Type, Disease Type, Application, End-User, Route of Administration and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Zoetis Inc., Merck Animal Health (Merck & Co., Inc.), Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Virbac S.A., Laboratorios HIPRA, S.A. (HIPRA), Benchmark Holdings plc (INVE Aquaculture & Benchmark Genetics), Skretting (Nutreco N.V.), Cargill Aqua Nutrition (Cargill, Incorporated), Grobest Group, Avanti Feeds Limited, Kemin Industries, Inc. (Kemin AquaScience), Organica Biotech Private Limited, Sanzyme Biologics Private Limited , ViAqua Therapeutics Ltd., Syndel Laboratories Ltd., Kyoto Biken Laboratories, Inc. , Vaxxinova International B.V., Nisseiken Co., Ltd. , Salem Microbes Private Limited, Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Segmentation:
Shrimp Disease Prevention & Therapeutics Market by Product Type -
• Disease Prevention
o Probiotics & Microbial Products
o Vaccines & Immunostimulants
o Functional Health Feeds & Nutraceuticals
o Biosecurity, Disinfectants & Diagnostics
o Disease-Resistant Broodstock & Genetics
• Therapeutics
o Antibiotics
o Antiparasitic & Antifungal Agents
o Antivirals & Supportive Therapeutics
o Chemical Disease-Control Treatments
Shrimp Disease Prevention & Therapeutics Market by Disease Type-
• Viral Diseases
o White Spot Syndrome Virus (WSSV)
o Taura Syndrome Virus (TSV)
o Yellow Head Virus (YHV) / Gill-Associated Virus (GAV)
o Infectious Myonecrosis Virus (IMNV)
o White Muscle / White Tail Viral Diseases
o Others
• Bacterial Diseases
o Vibriosis
o Acute Hepatopancreatic Necrosis Disease (AHPND/EMS)
o Vibrio-associated Hepatopancreatic Infections
• Bacterial Shell Diseases
o Chronic Bacterial Septicemia
o Parasitic & Microsporidian Diseases
o Enterocytozoon Hepatopenaei (EHP)
o Gregarine Parasitic Infections
o Protozoan Fouling Parasites
o Others
• Fungal & Opportunistic Pathogens
Shrimp Disease Prevention & Therapeutics Market by Route of Administration -
• Oral
• Water / Immersion / Bath Application
• Injectable Delivery
• Topical & External Application
• Others
Shrimp Disease Prevention & Therapeutics Market by End-User -
• Grow-Out Farms
• Hatcheries & Nurseries
• Integrated Farming & Feed Companies
• Diagnostic Laboratories & Research Institute
IoT Sensors & Predictive Analytics for Precision Aquaculture Market by Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• India
• Vietnam
• Indonesia
• Thailand
• Bangladesh
• Rest of Asia Pacific
Latin America-
• Brazil
• Mexico
• Ecuador
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Shrimp Disease Prevention and Therapeutics Market is estimated to grow at a 9.4% CAGR during the forecast period for 2026 to 2035.
Zoetis Inc., Merck Animal Health (Merck & Co., Inc.), Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Virbac S.A., Laboratorios HIPRA, S.A. (HIPRA), Benchmark Holdings plc (INVE Aquaculture & Benchmark Genetics), Skretting (Nutreco N.V.), Cargill Aqua Nutrition (Cargill, Incorporated), Grobest Group, Avanti Feeds Limited, Kemin Industries, Inc. (Kemin AquaScience), Organica Biotech Private Limited, Sanzyme Biologics Private Limited , ViAqua Therapeutics Ltd., Syndel Laboratories Ltd., Kyoto Biken Laboratories, Inc. , Vaxxinova International B.V., Nisseiken Co., Ltd. , Salem Microbes Private Limited, Others
Shrimp Disease Prevention and Therapeutics Market segmented by Product Type, Disease Type, Application, End-User, Route of Administration and By Region
Asia Pacific region is leading the Shrimp Disease Prevention and Therapeutics Market.